
Veracyte (VCYT) Stock Forecast & Price Target
Veracyte (VCYT) Analyst Ratings
Bulls say
Veracyte Inc. demonstrated strong growth in genomic test volume, achieving a 25% increase year-over-year, highlighted by an impressive 45% growth in urology tests from the Decipher platform. The company reported an adjusted EBITDA margin improvement of 690 basis points compared to the previous year, alongside a significant rise in testing revenue to $112.2 million, an increase of 24%. Additionally, management's guidance for an adjusted EBITDA margin of approximately 21.6% for 2025, elevated by ongoing adoption among existing customers and the introduction of larger new accounts, indicates a robust operational outlook.
Bears say
Veracyte Inc. is facing a negative outlook primarily due to slower-than-expected growth rates for its key cancer diagnostic tests, Decipher and Afirma, alongside anticipated weaker margin performance and earnings projections. Revenue growth has decelerated from 29% in 3Q24 to 21% in 4Q24, coupled with a slight decline in revenue per test, which fell approximately 1% year-over-year. Additionally, there are potential headwinds related to an exit from the VCYT subsidiary, which may impact consensus revenue estimates for 2025, thus raising concerns about sustained financial performance.
This aggregate rating is based on analysts' research of Veracyte and is not a guaranteed prediction by Public.com or investment advice.
Veracyte (VCYT) Analyst Forecast & Price Prediction
Start investing in Veracyte (VCYT)
Order type
Buy in
Order amount
Est. shares
0 shares